We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

135 hedge funds and large institutions have $1.1B invested in Viridian Therapeutics in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

246% more call options, than puts

Call options by funds: $7.59M | Put options by funds: $2.19M

87% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 15

46% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 37

11% more funds holding

Funds holding: 122 → 135 (+13)

2.05% less ownership

Funds ownership: 102.45% → 100.39% (-2.1%)

9% less capital invested

Capital invested by funds: $1.21B → $1.1B (-$110M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
135
Holders Change
+13
Holders Change %
+10.66%
% of All Funds
2.15%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.11%
New
28
Increased
54
Reduced
37
Closed
15
Calls
$7.59M
Puts
$2.19M
Net Calls
+$5.4M
Net Calls Change
+$5.51M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$36.2M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$33.4M
3
HRCM
Hood River Capital Management
Florida
+$18.2M
4
PCH
Polar Capital Holdings
United Kingdom
+$17.6M
5
State Street
State Street
Massachusetts
+$17.3M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$35.9M
2
BI
BVF Inc
California
-$34.3M
3
DTC
Deep Track Capital
Connecticut
-$17.3M
4
KCM
Kynam Capital Management
New Jersey
-$15.7M
5
TCM
TCG Crossover Management
California
-$10.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
26
Kynam Capital Management
New Jersey
$13.8M -$15.7M -491,094 -47%
AG
27
Artal Group
Luxembourg
$12.8M +$16.2M +504,978 New
EAM
28
Eagle Asset Management
Florida
$11.7M +$14.8M +461,665 New
Morgan Stanley
29
Morgan Stanley
New York
$11M +$3.14M +97,832 +29%
DCM
30
Driehaus Capital Management
Illinois
$10.3M -$1.2M -37,555 -8%
Northern Trust
31
Northern Trust
Illinois
$9.44M +$296K +9,237 +3%
Goldman Sachs
32
Goldman Sachs
New York
$9.03M +$3.57M +111,236 +46%
FAM
33
Fred Alger Management
New York
$8.23M -$3.35M -104,597 -24%
5VM
34
5AM Venture Management
California
$7.12M -$641K -20,000 -7%
Bank of America
35
Bank of America
North Carolina
$6.48M +$4.47M +139,443 +121%
Deutsche Bank
36
Deutsche Bank
Germany
$6.46M +$7.6M +237,028 +1,387%
AVA
37
Atlas Venture Advisors
Massachusetts
$5.33M – – –
Norges Bank
38
Norges Bank
Norway
$5.31M +$2.39M +74,600 +56%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$4.5M +$1.92M +59,913 +51%
GTC
40
Ghost Tree Capital
New York
$4.45M +$321K +10,000 +6%
Citigroup
41
Citigroup
New York
$4.28M +$3.55M +110,746 +193%
BI
42
BVF Inc
California
$4.27M -$34.3M -1,070,974 -86%
ACP
43
Acuta Capital Partners
California
$4.27M -$7.33M -228,500 -58%
Fidelity Investments
44
Fidelity Investments
Massachusetts
$3.67M +$4.58M +142,950 +11,932%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$3.55M -$414K -12,918 -8%
Connor, Clark & Lunn Investment Management (CC&L)
46
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.47M +$152K +4,726 +4%
KFO
47
Kopp Family Office
Minnesota
$3.34M +$2.15M +66,900 +104%
ECM
48
ExodusPoint Capital Management
New York
$3.23M -$2.04M -63,753 -33%
Wellington Management Group
49
Wellington Management Group
Massachusetts
$3.16M +$125K +3,893 +3%
EGI
50
EAM Global Investors
California
$3.13M -$931K -29,042 -19%
1
2
3 4 5

VRDN Hedge Fund Activity: Q1 2023 in Review

135 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2023, worth a combined $1.1B — down 9.1% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VRDN positions and 15 closed out — a net gain of 13 holders — while 54 added to existing stakes and 37 trimmed.

The largest buyer was RA Capital Management, adding an estimated $36.2M. The largest seller was Citadel Advisors, cutting an estimated $35.9M.

  • 135 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2023, up from 122 in Q4 2022.
  • Funds reported $1.1B of Viridian Therapeutics stock for Q1 2023, down 9.1% quarter-over-quarter.
  • 28 funds opened new Viridian Therapeutics positions in Q1 2023 and 15 closed out, a net change of +13 holders.
  • The largest Viridian Therapeutics buyer in Q1 2023 was RA Capital Management, an estimated $36.2M added.
  • The largest Viridian Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $35.9M sold.

Based on aggregated 13F filings for Q1 2023.